503A and 503B: Vocabulary for Cross-Functional Life-Science Teams

Life-science organizations sometimes encounter the terms 503A and 503B when discussing compounded drug products prepared under the Federal Food, Drug, and Cosmetic Act. That domain is not the same as purchasing catalog peptides sold with research-use intent from specialty suppliers. However, vocabulary alignment across purchasing, quality, and legal groups prevents mix-ups in internal SOPs.

503A traditionally refers to state-licensed pharmacy compounding for patient-specific prescriptions, subject to specific conditions. 503B refers to registered outsourcing facilities that compound under heightened federal standards. Both routes concern drug compounding, not the sale of RUO reagents to laboratories for non-clinical research. For a discussion of when prescribing applies vs. RUO, see can doctors prescribe research peptides.

Research-use materials are positioned as reagents for laboratory and analytical work. The purchasing conversation centers on COA review, storage, and fit to protocol, not a patient-specific prescription. When organizations need a regulatory refresher, cross-link to the RUO documentation checklist and the glossary: RUO.

Commercial intent comparison pages and category hubs on PurePep Vital (for example compare and shop by category) are framed for research buyers who are evaluating offer clarity and third-party testing claims—not compounding of patient prescriptions.